C WorldWide Group Holding A S boosted its position in Axovant Sciences Ltd. (NYSE:AXON) by 20.0% during the second quarter, according to its most recent filing with the SEC. The firm owned 131,500 shares of the biotechnology company’s stock after buying an additional 21,900 shares during the period. C WorldWide Group Holding A S’s holdings in Axovant Sciences were worth $3,049,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. bought a new stake in shares of Axovant Sciences during the first quarter worth about $219,000. Norges Bank bought a new stake in shares of Axovant Sciences during the fourth quarter worth about $508,000. AQR Capital Management LLC bought a new stake in shares of Axovant Sciences during the fourth quarter worth about $139,000. Primecap Management Co. CA raised its stake in shares of Axovant Sciences by 300.1% in the first quarter. Primecap Management Co. CA now owns 2,878,930 shares of the biotechnology company’s stock worth $43,011,000 after buying an additional 2,159,428 shares during the period. Finally, Point72 Asset Management L.P. raised its stake in shares of Axovant Sciences by 1,718.3% in the first quarter. Point72 Asset Management L.P. now owns 209,100 shares of the biotechnology company’s stock worth $3,124,000 after buying an additional 197,600 shares during the period. Institutional investors own 94.35% of the company’s stock.

Axovant Sciences Ltd. (AXON) opened at 22.27 on Friday. Axovant Sciences Ltd. has a 12-month low of $11.01 and a 12-month high of $26.49. The company has a 50 day moving average of $22.92 and a 200-day moving average of $19.11. The stock’s market capitalization is $2.37 billion.

Axovant Sciences (NYSE:AXON) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.65) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by $0.12. On average, equities research analysts forecast that Axovant Sciences Ltd. will post ($2.32) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Axovant Sciences Ltd. (NYSE:AXON) Stake Increased by C WorldWide Group Holding A S” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.watchlistnews.com/axovant-sciences-ltd-nyseaxon-stake-increased-by-c-worldwide-group-holding-a-s/1478003.html.

AXON has been the subject of a number of research analyst reports. BidaskClub raised shares of Axovant Sciences from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Jefferies Group LLC reaffirmed a “buy” rating and set a $31.00 price objective on shares of Axovant Sciences in a report on Tuesday, April 18th. CIBC increased their price objective on shares of Axovant Sciences from $30.00 to $33.00 and gave the company a “neutral” rating in a report on Tuesday, April 18th. Oppenheimer Holdings, Inc. increased their price objective on shares of Axovant Sciences from $30.00 to $33.00 and gave the company a “neutral” rating in a report on Monday, April 17th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Axovant Sciences in a report on Wednesday, June 21st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $28.50.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axovant Sciences Ltd. (NYSE:AXON).

Institutional Ownership by Quarter for Axovant Sciences (NYSE:AXON)

Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.